Press Releases

PRINCETON, N.J., July 31, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that two posters outlining ongoing formulation efforts to develop a trivalent thermostabi

Partnership Facilitated by Major Investment from Arsenal Capital Partners NEW YORK, July 31, 2019 /PRNewswire/ -- Caprion Biosciences ("Caprion") and HistoGeneX announced today they have agreed to combine their respective businesses. The new partnership creates a global leader in immune monitoring, protein characterization, and tissue pathology solutions

WALTHAM, Mass., July 31, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its second quarter 2019 financial results on Wednesday, August 7, after the cl

MISGAV, Israel, July 31, 2019 /PRNewswire/ -- MetoMotion, a portfolio company of The Trendlines Group Ltd. (SGX: 42T) (OTCQX: TRNLY), announced that it has completed an investment round of $1.5 mil

REHOVOT, Israel, July 31, 2019 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today its financial results for the second quarter ending June 30, 2019.

LOS ANGELES, July 31, 2019 /PRNewswire/ -- Bio-Up Mimetic Technologies Inc., a biotechnology company that invented a patent-pending

COSTA MESA, Calif., July 31, 2019 /PRNewswire/ -- While 9.6% of Americans have used telehealth services, nearly three-fourths (74.3%) say they either don't have access or are unaware of telehealth options, according to a J.D. Power pulse survey tracing telehealth user experience, hurdles to adoption and real-world patient concerns.

INCHEON, South Korea, July 31, 2019 /PRNewswire/ -- Samsung BioLogics (SBL) and UCB have agreed to an additional drug substance manufacturing deal under which SBL will also produce UCB's anti-tau candidate to treat progressive supranuclear palsy, pending regulatory approvals. UCB's anti-tau candidate is currently in Phase I clinical studies.

DENVER, July 31, 2019 /PRNewswire/ -- DaVita Health Solutions today announced two additions to its leadership team: Dr. Dorothy "Dody" Fisher, national medical dir

IRVING, Texas, July 31, 2019 /PRNewswire/ -- Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that